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Abstract: This study aimed to assess how to enhance the value of 18F-Fluorodeoxyglucose (FDG)
PET/CTs for glioma grading and better delineation of the tumor boundary by glucose loading.
In mouse models of brain tumor using U87MG cells, 18F-FDG-PET images were obtained after fasting
and after glucose loading. There was a significant difference in the tumor-to-normal cortex-uptake ratio
(TNR) between the fasting and glucose-loading scans. 14C-2-Deoxy-D-glucose (14C-DG) uptake was
measured in vitro using U87MG, U373MG and primary neurons cultured with different concentrations
of glucose. The tumor-to-neuron ratio of 14C-DG uptake increased with up to 10 mM of glucose.
Finally, 10 low-grade and 17 high-grade glioma patients underwent fasting and glucose loading
18F-FDG PET/CT and the TNR was compared between scans. The effect of glucose loading was
significant in high-grade but not in low-grade gliomas. The receiver operating characteristic curve
analyses with a cut-off TNR of 0.81 showed a higher area under the curve after glucose loading than
fasting for differentiating low-grade versus high-grade gliomas. In addition, the glucose loading
PET/CT was more useful than the fasting PET/CT for the discrimination of oligodendrogliomas from
IDH-wildtype glioblastomas. Glucose loading resulted in a greater reduction in 18F-FDG uptake in
the normal cortex than in tumors, which increases the usefulness of 18F-FDG PET/CT for grading.
Keywords: glioma; glucose loading; 18F-FDG PET/CT; grading
1. Introduction
18F- Fluorodeoxyglucose (FDG) PET/CTs provide information based on the increased glycolysis
of cancer cells, and are successfully used for the diagnosis, staging, treatment response monitoring,
and prognostication of cancers. In cerebral gliomas, higher 18F-FDG uptake correlates with higher
pathological grades and patient prognosis [1]. Although 18F-FDG PET/CT is accessible and validated
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for functional tumor imaging, it has limitations for cerebral gliomas. Most significantly, there is a high
rate of physiologic glucose uptake in the cerebral cortex, which can be as high as high-grade tumors or
higher than low-grade gliomas [2,3]. Therefore, accurate characterization of the tumor and delineation
of the tumor boundary is challenging with 18F-FDG PET/CT.
Radiolabeled amino acid tracers, which are associated with increased cellular proliferation and
protein synthesis are considered superior alternatives to 18F-FDG for cerebral gliomas. They are excellent
for tumor detection and delineation due to their low background uptake in the normal cortex and high
radiolabeled amino acid uptake in tumors, including low-grade gliomas [4]. However, the predictive
values for grading are less clear because of the significant overlap in amino acid metabolism between
grades [5]. In particular, the ability to discriminate oligodendrogliomas (ODs) from high-grade
astrocytic gliomas is challenging with radiolabeled amino acid tracers. Magnetic resonance imaging
(MRI) has been widely used as a diagnostic modality for gliomas. However, enhanced MRI has
limitations in that it cannot accurately provide the stage of the glioma or discriminate clearly between
the tumor and the surrounding edema [6,7]. Recently, advanced MRI techniques, have been used
to provide functional, physiological and molecular information on glioma, including perfusion MRI
using relative cerebral blood volume (rCBV) and magnetic resonance spectroscopy (MRS) using the
concentration of water-soluble metabolites. However, MRS is not able to provide a clear image due
to the presence of susceptibility artefacts and it has methodological limitations due to the lack of
standardization for image acquisition and processing [8].
The results of different studies vary with regard to the correlation between the blood glucose
level and 18F-FDG uptake in different organs and tumors. However, all studies agree that there is
a significant inverse relationship between blood glucose level and 18F-FDG uptake in the normal
cerebral cortex [9–12]. A blood glucose level above 110 mg/dL decreases 18F-FDG uptake in the cerebral
cortex [12]. The guidelines for tumor imaging recommend at least 4 h of fasting before 18F-FDG PET/CT
to avoid reducing the tumor detection sensitivity [13,14]. However, for cerebral gliomas, an increased
blood glucose level might be beneficial because it decreases the background 18F-FDG uptake in the
cerebral cortex, and thus ensures high tumor-to-normal cortex contrast. In this study, the effect of
various blood glucose levels on 18F-FDG uptake in the normal cerebral cortex and cerebral gliomas,
and the blood glucose level required to obtain the best TNR were investigated in mouse tumor models,
glioblastoma (GBM) cell lines, and patients with cerebral gliomas.
2. Results
2.1. TNR of 18F-FDG Uptake Was Increased by Glucose Loading in a Mouse GBM Model
At the time of the 18F-FDG injection, the mean blood glucose level of mice was 74.66 ± 7.42 mg/dL
after fasting and 122.53 ± 21.19 mg/dL after glucose loading. The tumor was difficult to delineate
visually on the 18F-FDG/PET images due to the high 18F-FDG uptake in the normal cortex after fasting.
On the contrary, after glucose loading, 18F-FDG uptake in the normal cortex decreased significantly,
which resulted in clear delineation of the tumor on the PET images (Figure 1a). The decreased rate in
the standardized uptake value (SUV) after glucose loading was 35.9% in the tumor (SUVmax) and
47.2% in the normal cortex (SUVmean) (Figure 1b). There was a statistically significant difference in
the TNR between the fasting and glucose loading scans (0.95 vs. 1.15, p = 0.019) (Figure 1c).




Figure  1.  (a)  18F‐FDG  PET/MRI  images  of mice U87MG  xenograft models  after  fasting  and with 
glucose loading. (b) Maximum standardized uptake value (SUVmax) in the tumor and normal cortex 
after  fasting and glucose  loading.  (c) Tumor  to contralateral cortex  ratio after  fasting and glucose 
loading. 
2.2. 14C‐DG Uptake Ratio of GBM Cells to Neurons Was Enhanced at High Glucose Levels 
For  in  vitro  cell  uptake,  we  replaced  positron‐emitting  nuclide  18F‐FDG  with  beta‐decay 
radionuclide  14C‐DG, which has  the same structure and  function, but  is easier  to use  in vitro. We 
screened 14C‐DG uptake in mouse primary neurons, astrocytes, U87MG and U373MG cells and found 
that  the  14C‐DG  uptake  in  astrocytes  was  not  significantly  different  regardless  of  the  glucose 
concentration in the media. Therefore, we evaluated changes in 14C‐DG uptake with different glucose 










Figure 1. (a) 18F-FDG PET/MRI images of mice U87MG xenograft models after fasting and with glucose
loading. (b) Maximum standardized uptake value (SUVmax) in the tumor and normal cortex after
fasting and glucose loading. (c) Tumor to contralateral cortex ratio after fasting and glucose loading.
2.2. 14C-DG Uptake Ratio of GBM Cells to Neurons Was Enhanced at High Glucose Levels
For in vitro cell uptake, we replaced positron-emitting nuclide 18F-FDG with beta-decay
radionuclide 14C-DG, which has the same structure and function, but is easier to use in vitro.
We screened 14C-DG uptake in mouse primary neurons, astrocytes, U87MG and U373MG cells
and found that the 14C-DG uptake in astrocytes was not significantly different regardless of the glucose
concentration in the media. Therefore, we evaluated changes in 14C-DG uptake with different glucose
levels in the media-only in the mouse primary neurons, U373MG and U87MG cells. The concentration
of cold glucose in the media was varied at 0, 1, 2.5, 5, 10, and 15 mM. 14C-DG uptake was highest at 0 mM
of glucose in all cell types (U87MG, 3.11 ± 0.81, CPM%/mg; U373MG, 2.89 ± 0.41; neuron, 3.54 ± 0.37,
CPM%/mg). While 14C-DG uptake decreased as the glucose concentration in the media increased,
there were differences in the rates of decrease among the primary neurons, U87MG and U373MG cells
(Figure 2a). The U87MG tumor-to-neuron ratio of 14C-DG uptake increased continuously up to 10 mM
of glucose concentration (1.00 at 0 mM; 1.25 at 1 mM; 1.72 at 2.5 mM; 2.11 at 5 mM; 2.74 at 10 mM),
and then decreased to 2.29 at 15 mM (Figure 2b). The U373MG tumor-to-neuron ratio of 14C-DG
uptake (1.00 at 0 mM; 0.77 at 1 mM; 1.11 at 2.5 mM; 1.56 at 5 mM; 2.23 at 10 m ; 1.71 at 15 mM) had a
similar pattern toU87 G.


































Figure 2. In vitro 14C-2-Deoxy-D-glucose (14C-DG) uptake in U87MG, U373MG and mouse primary
neurons. (a) 14C-DG uptake and (b) U87MG tumor-to-neuron ratio for different glucose concentrations
in the media.
2.3. TNR of 18F-FDG PET/CT Images Was Increased by Glucose Loading in Patients with High-Grade Gliomas
The clinicopathologic characteristics of the patients are summarized in Table 1. Of the 27 patients
with histologically confirmed cerebral gliomas, 10 (37.0%) had WHO grade II tumors, 7 (25.9%) had
grade III tumors, nd 10 (37.0%) had grade IV tumors. The mean blood glucose level o i
at e time of 18F-FDG injection was 98.9 mg/dL after fasting and 203.1 mg/dL after glucose loading.
In th glucose lo ding study, the changes in blo d glucose levels ver the course of the study are
shown in Figure 3.
Table 1. Patient characteristics.
Characteristic Values




WHO 2016 grade, n (%)
Grade II 10 (37.0%)
Grade III 7 (25.9%)
Grade IV 10 (37.0%)
Histology, n (IDH-mutant/wildtype)
Astrocytoma 20
Grade II 6 (5/1)
Grade III 4 (1/3)




WHO, World Health Organization.
In all patients, the median SUVmax of tumors was 8.84 (interquartile range (IQR), 7.27–10.38)
after fasting and 5.13 (IQR, 3.52–5.87) after glucose loading. The median SUVmean of the contralateral
normal cortex was 9.75 (8.47–11.17) after fasting and 4.70 (3.23–5.34) after glucose loading. In the
case of high-grade glioma, glucose loading induced a significant reduction in 18F-FDG uptake in the
tumor, and more in the normal cortex (42.5% in tumors versus 53.6% in the normal cortex, p = 0.0261)
(Figure 4a).
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Figure 4. 18F-FDG PET/CT (upper panel) and FLAIR and T1 enhanced MRI images (bottom panel) after
fasting and glucose loading in a patient with (a) high-grade and (b) low-grade glioma. (a) Involvement
of glioblastoma was pathologically confirmed in the left frontal lobe and corpus callosum (red arrow)
in the glioblastoma. (b) Diffuse astrocytoma, IDH-mutant was pathologically confirmed in the right
frontal lobe (red arrow).
When the tumors were categorized as high (Grade III and IV, n = 17) and low-grade (Grade II,
n = 10) gliomas, the effect of glucose loading was different (Figure 4a,b). In high-grade gliomas,
the median TNR was 0.96 (IQR, 0.78–1.07) after fasting and 1.20 (IQR, 1.01–1.28) after glucose loading
(increase of 25%, p = 0.0167). However, in low-grade gliomas, the median TNR was 0.66 (IQR, 0.52–0.77)
after fasting and 0.68 (IQR, 0.55–0.76) after glucose loading (p = 0.7055) (Table 2). With a cut-off TNR
of 0.81 for differentiating low-grade versus high-grade gliomas, the receiver operating characteristic
(ROC) analyses showed a higher area under the curve (AUC) after glucose loading than that after
fasting (0.953 vs. 0.847; p = 0.0431).
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Table 2. The tumor-to-normal brain cortex uptake ratio (TNR) in glioma.
State High-Grade Median (IQR)(n = 17)
Low-Grade Median (IQR)
(n = 10)
Glucose loading 1.20 (IQR 1.01–1.28) 0.68 (IQR 0.55–0.76)
Fast 0.96 (IQR 0.78–1.07) 0.66 (IQR 0.52–0.77)
(p value) 0.0167 0.7055
Glucose loading PET/CT was more useful than fasting PET/CT for the discrimination of ODs from
IDH-wildtype GBMs. GBMs showed higher TNRs (median, 1.71; IQR, 1.28–2.19) than Grade II ODs
(median, 0.76; IQR, 0.65–1.05; p < 0.001, adjusted) and Grade III ODs (median, 1.17; IQR, 1.01–1.24;
p = 0.022, adjusted) in glucose loading PET/CT (Figure 5a). In contrast, the TNRs differed significantly
between IDH-wildtype GBMs (median, 1.58; IQR, 1.03–1.70) and Grade II ODs (median, 0.77;
IQR, 0.64–1.05; p = 0.019, adjusted), but there was no significant difference in TNRs between
IDH-wildtype GBMs and Grade III ODs (median, 0.90; IQR, 0.84–1.11; p = 0.148, adjusted) after
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1.24;  p  =  0.022,  adjusted)  in  glucose  loading  PET/CT  (Figure  5a).  In  contrast,  the  TNRs  differed 
significantly between IDH‐wildtype GBMs (median, 1.58; IQR, 1.03–1.70) and Grade II ODs (median, 







Figure 5. 18F-FDG TNRs of grade II oligodendrogliomas, grade III anaplastic oligodendrogliomas,
and g ade IV I H-wildtype glioblastomas in (a) glucose loading 18F-FDG PET/CT and (b) fasting
18F-FDG PET/CT.
3. Discussion
A high blood glucose level decreases radioactive glucose uptake in tumors. Therefore, at least 4 h
of fasting is recommended so as not to decrease detection sensitivity before an 18F-FDG PET/CT in
patients with cerebral gliomas [13,14]. However, fasting increases background 18F-FDG uptake in the
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normal cortex. On the other hand, high blood glucose levels decrease 18F-FDG uptake in the normal
cortex, with the risk of decreasing 18F-FDG uptake in the tumors. In this prospective study, we found
that glucose loading led to a greater reduction in 18F-FDG uptake in the normal cortex than in tumors,
especially in high-grade gliomas. Thus, the TNR increased after glucose loading, which increased the
usefulness of 18F-FDG PET/CT for grading cerebral gliomas.
Orthotopic mouse tumor models using the human GBM cell line (U87MG) were imaged twice
with 18F-FDG PET (once with fasting and once with glucose loading) to determine the feasibility of
glucose loading for enhancing tumor to normal cortex contrast. After fasting, 18F-FDG uptake in
the normal cerebral cortex was higher than in the tumor. In fact, the tumor was shown as a round,
cold defect compared to the cortex, and the delineation of the tumor for the SUV measurement was
difficult without MRI co-registration. In contrast, 18F-FDG uptake in the normal cortex decreased
significantly, and there was a clear delineation of the tumor on PET/CT images after glucose loading.
The tumor appeared clear, and the SUV measurement could be performed without the help of MRI
co-registration. The higher reduction (49.2%) in the SUVmax in the normal cortex compared to that
(35.9%) in the tumor led to a significantly higher TNR after glucose loading. The mouse tumor models
showed the potential benefits of glucose loading in terms of increasing the contrast between the tumor
and the normal cortex.
Studies have evaluated the effect of high blood glucose levels on 18F-FDG uptake in the cerebral
cortex, liver, and blood pool. The normal cerebral cortex is the organ that is most consistently affected
by different levels of blood glucose. In a recent report, the mean brain SUVmax reduced gradually
with a blood glucose level of 110 mg/dL or higher. The SUVmax of the cerebral cortex was reduced by
20, 35, 50, 60, and 65% for blood glucose ranges of 111–120, 121–140, 141–160, 161–200, and greater
than 20 mg/dL, respectively [9]. This earlier study suggested a formula to correct SUV in which the
measured SUVmax was multiplied by a reduction factor of 1.25, 1.5, 2, 2.5, and 2.8 for the same blood
glucose ranges. Regardless, there is limited information on the effect of various blood glucose levels
on 18F-FDG uptake in cerebral gliomas and the blood glucose level, and which level can obtain the
highest TNR. Using the U87MG, U373MG cell lines and primary neuron with different concentrations
of glucose ranging from 0 to 15 mM, we found decreased 14C-DG uptake at all glucose levels in all three
types of cells, but the rates of decrease differed among the primary neurons, U87MG and U373MG cells.
14C-DG uptake of U87MG and U373MG cells showed similar values to neurons at low concentrations
of glucose, but higher values than neurons at high concentrations of glucose. The tumor-to-neuron
ratio increased continuously up to 10 mM and then decreased from 15 mM. Glucose uptake remained
higher in the tumor cells than the primary neurons even at higher concentrations of glucose.
So far, only one report has evaluated the effect of high blood glucose levels on brain tumor
detection. Ishizu et al. showed that glucose loading enhanced the detection of brain tumors in eight
patients with recurrent or residual glioma and one patient with brain metastasis [15]. They started the
infusion of 10% glucose solution 10–15 min before the 18F-FDG injection, and maintained it until the end
of the study, finally providing approximately 500 mL (50 g of glucose). The glucose loading decreased
18F-FDG uptake in the cerebral cortex (54.2% ± 13.8%) in an almost inverse proportion to the glucose
level while the tumors also showed a decrease (42.5% ± 15.6%), and the resulting TNR increased by
26.0% ± 5.7%. Although these results are feasible, the limited number of patients included in the study
(6 GBMs, 1 OD, 1 astrocytoma) make it difficult to accurately evaluate the value of glucose loading.
In this study, based on the results of the previous report and our cell line and mouse studies,
we performed 18F-FDG PET/CT scans after fasting and intravenous infusion of 250 mL of 10% glucose
for a total of 35 min, 25 min before 18F-FDG injection and 10 min after the injection. Glucose loading
induced a significant reduction in 18F-FDG uptake in both the tumor and normal cortex (42.5% in
tumors vs. 53.6% in the normal cortex, p = 0.0261). The effect of high blood glucose was more beneficial
in high-grade than low-grade gliomas. In high-grade gliomas, the median TNR increased by 25% after
glucose loading compared to fasting. In low-grade gliomas, there were no significant differences in
the median TNRs between fasting and glucose loading. Previously, fasting FDG PET/CT studies have
Cancers 2020, 12, 1977 8 of 12
shown relatively low AUC values for grading high- vs. low-grade gliomas (AUC: 0.76–0.80) [15,16].
MRI studies have also shown similar AUC values (0.78–0.86) [17,18]. In our study, with a TNR cut-off
of 0.81, we found a significantly higher AUC value for grading after glucose loading than fasting
(0.953 vs. 0.847; p = 0.0431). This high diagnostic power could help patients who cannot undergo
any surgical procedures or biopsy due to the location of lesions. Further studies are needed to see
whether additional data from advanced MRI techniques, including perfusion MRI, apparent diffusion
coefficient (ADC), and MRS will improve the performance of glucose loading 18F-FDG PET/CT.
Currently, radiolabeled amino acid tracers such as 11C-methionine,
3,4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA), and O-(2-18F-fluoroethyl)-L-tyrosine
(18F-FET) are preferred to 18F-FDG. Other than lower background uptake in the cortex, they are
better at showing IDH-wildtype low-grade gliomas [16–18]. However, their value in differentiating
low-grade vs. high-grade glioma needs further validation due to the high uptake in ODs, which is as
high as that for high grade IDH1-wildtype gliomas [4]. In this study, glucose loading 18F-FDG PET/CT
was able to discriminate ODs from IDH-wildtype GBMs. Although high and variable normal cortical
uptake has limited the use of 18F-FDG PET/CT, 18F-FDG has advantages in representing the metabolic
hallmarks of malignant tumors. Based on our study, 18F-FDG PET/CT with glucose loading might be
an opportunity to revisit the use of 18F-FDG in patients with cerebral gliomas. Additional studies
comparing 18F-FDG PET/CT with glucose loading and amino acid radiotracers might help to further
evaluate this issue.
There were limitations to this study. Patients with diabetes were not included because their
baseline blood glucose levels can be highly variable. Further studies are needed to personalize glucose
loading methods based on a patient’s individual diabetic status and to control excessive hyperglycemia.
Secondly, the metabolic tumor volume related to patient prognosis was not measured, although it was
easier to delineate tumor margins due to the lower background in high-grade tumors. Future studies
are needed to investigate whether 18F-FDG PET/CT after glucose loading makes it easier to determine
the resection margin and metabolic tumor volume of high-grade cerebral gliomas.
4. Materials and Methods
4.1. Glioblastoma Mouse Model
All animal experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) of Yonsei University College of Medicine (approval code 2018-0202). Balb/c nude female mice
6 to 8 weeks old (OrientBio, Seongnam, Korea) were used for all animal experiments. U87MG (human
glioblastoma) cells (5× 105 in 2 µL phosphate buffered saline [PBS]) were stereotactically implanted into
the right frontal lobe of the mice. The glioma-bearing mice were imaged 4 weeks post-implantation.
4.2. Animal PET
All mice (n = 5) were imaged twice on a microPET scanner (Inveon, Siemens Healthcare, Erlangen,
Germany), once after overnight fasting and again after glucose loading. For 18F-FDG PET imaging,
the mice were anesthetized with 2.5% isoflurane. In the glucose loading study, blood glucose
levels were measured using a glucometer (Accu-Chek Performa, Accu-Chek Inform II test strips;
Roche Diagnostics, Indianapolis, IN, USA) 5 min after the subcutaneous injection of 5% dextrose
solution (200 µL). Then, the mice were intravenously administered with 18F-FDG (7.4 MBq/0.2 mL
in saline) and allowed to rest for 1 h on a heating pad under 2% isoflurane anesthesia. 18F-FDG PET
data were acquired for 10 min. After imaging, the animals were kept under a heat lamp until
awake, then placed in an isolation room for 24 h to eliminate radiation hazards. The PET data
were reconstructed with three-dimensional (3D) ordered subset expectation-maximization (OSEM)
with 2 iterations and 18 subsets. The matrix size was 128 × 128 × 159, and the voxel size was
0.776 × 0.776 × 0.796 mm. The SUV was calculated by the tissue concentration kBq/cm3 per injected
dose (kBq per gram of body weight).
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4.3. Animal Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) of the implanted brain tumor was performed using a
9.4 T preclinical MRI (Bruker BioSpec 94/20 USR, Ettlingen, Germany; software: ParaVision 5.0)
with water-cooled gradient coils (maximum gradient strength, 400 mT/m) before PET imaging.
The mice were kept warm on a heating pad and anesthetized by 2% isoflurane during the MRI,
which was performed with a respiration-triggered and fat-suppressed T2-weighted rapid acquisition
with relaxation enhancement (RARE) sequence [19]. A two-dimensional (2D) set of axial images were
acquired (TR, 4900 ms; TEeff, 24 ms; pixel-size, 208 µm2; slice-thickness, 500 µm).
4.4. Animal Image Analysis
Image processing and analyses were performed using PMOD software (PMOD Technologies
Ltd., Zurich, Switzerland). 18F-FDG PET images were co-registered to the corresponding T2-weighted
MRI images and manually transformed for minor misalignments. Two regions of interest (ROI) were
manually drawn over the MRI images (one for the tumor to measure the maximum SUV and the other
for the contralateral cortex to measure the mean SUV). The TNR were calculated and the fasting and
glucose loading scans were compared.
4.5. In Vitro 14C-DG Uptake in Glioma Cells and Neurons
The cells (U87MG, U373MG and mouse primary neuron: 5 × 104) were seeded in 1 mL growth
medium per well in 24-well plates and incubated in a standard culture medium for 24 h. The cells were
washed twice with glucose-free medium and cultured in 0, 1, 2.5, 5, 10, and 15 mM glucose-concentration
medium for 2 h. Subsequently, 14C–DG (PerkinElmer, Waltham, MA, USA) 3.7 kBq/mL was added
to each sample, and the cells were incubated for 30 min. Then, the medium was removed and the
cells were rinsed twice with ice-cold PBS. The resultant cells were lysed with 500 µL of 0.2 N NaOH
for 2 h at room temperature. The radioactivity was measured with a liquid scintillation counter
(Tri-Carb, PerkinElmer, Waltham, MA, USA). The measured radioactivity was normalized to protein
concentration by previously described methods [20]. The experiments were performed three times
using three replicates for each condition.
4.6. Patients
This prospective study included 27 patients suspected of cerebral gliomas (11 men, 16 women;
median age, 50.0 years; range, 27–75 years) between June 2019 and December 2019. All patients
had undergone contrast-enhanced MRI (CE-MRI) and two 18F-FDG PET/CT scans, one after fasting
and the other after glucose loading. The interval between the two 18F-FDG PET/CT scans was 1 to
14 days, with a median interval of 1 day. Patients underwent surgery shortly after imaging (median,
3 days; range, 1–20 days). No therapeutic intervention, such as any other surgery, radiotherapy,
or chemotherapy was performed before surgery in any of the patients. All gliomas were classified
using the 2016 World Health Organization (WHO) guidelines. The Institutional Review Board of
Yonsei University College of Medicine approved this prospective study (approved code: 2018-0202),
and informed consent was obtained from all patients (IRB No. 4-2019-0455). This study was registered
at cris.nih.go.kr (KCT0004466).
4.7. 18F-FDG PET/CT Protocol
For fasting scans, all patients fasted for at least 6 h, then, blood glucose concentration was
confirmed as less than 140 mg/dL before an injection of 18F-FDG. For glucose loading scans, all patients
were asked to fast for at least 6 h to ensure their blood glucose level was less than 140 mg/dL. The glucose
loading was started by intravenous infusion of 250 mL of 10% glucose solution, with 200 mL given
first for 25 min at a rate of 8 mL/min, then, approximately 5.5 MBq of 18F-FDG per kilogram of body
weight was administered, and finally, the remaining 50 mL of 10% glucose solution was further infused
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for 10 min (infusion speed of 5 mL/min). Blood glucose levels were measured five times: on arrival,
just before 18F-FDG injection, 10 min after 18F-FDG injection, before scanning, and after scanning.
Imaging was performed using a PET/CT scanner (Discovery 600, GE Healthcare, Waukesha, WI,
USA) with an axial field-of-view of 15.7 cm and a spatial resolution of 4.0 mm at full-width at half
maximum at 1 cm from center. Sixty minutes after the 18F-FDG injection, CT images were obtained with
an eight-slice helical CT unit (Light Speed, GE Healthcare, Waukesha, WI, USA) using the following
parameters: 120 kVp, 200 mA; 0.8 s rotation time; 3.3 mm scan reconstruction; 25 cm field-of-view;
and a 256 × 256 matrix. Whole-brain, 3D PET images were obtained over 10 min. PET data were
reconstructed iteratively using an ordered-subset expectation-maximization algorithm. The CT datasets
were used for attenuation correction.
4.8. Data Analysis
PET/CT images were reviewed and analyzed on a dedicated workstation by two nuclear medicine
physicians who reached consensus. The PET/CT images were registered to contrast-enhanced MRI
images using a fusion software (MIM-6.5; MIM Software Inc., Cleveland, OH, USA). A volume of
interest (VOI) was manually drawn over the hottest area of each tumor, and the SUVmax of the tumor
was measured. When no increases in 18F-FDG uptake were observed, the SUVmax was measured
within the boundary of the tumor on the MRI images. The SUV of a VOI was calculated as follows:
(decay-corrected activity (kBq per tissue volume (mL))/(injected 18F-FDG activity (kBq) per body mass
(g)). To obtain reference (background) regions, three VOIs were manually drawn in the regions of the
contralateral cerebral cortex with a normal appearance, the SUVmean values of the three VOIs were
averaged, and the TNR was calculated.
4.9. Statistical Analysis
The Mann–Whitney U test was used to compare the TNR of the 18F-FDG uptake on PET after
fasting versus after glucose loading. ROC analysis was used to compare the diagnostic performance of
the two 18F-FDG PET/CT protocols for glioma grading. The Bonferroni methods was used in post hoc
analyses. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 25
(IBM Corp, Armonk, NY, USA). Except for post hoc analyses, a p-value less than 0.05 was considered
statistically significant.
5. Conclusions
Compared to fasting, glucose loading resulted in a higher tumor to normal cortex contrast
in high-grade gliomas, and subsequently, improved glioma grading and the discrimination of
oligodendrogliomas from IDH-wildtype glioblastomas.
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